Market research
REPL Replimune Group Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 19.3333
- Dividend yield
- Not available
- Beta
- 0.9
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US76029N1063
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 19.3333
- Dividend yield
- Not available
- Beta
- 0.9
About
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the REPL discussion.
5 years, 4 months ago
Replimune Group, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Replimune Group, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 34.6% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.2% to $-14M since the same quarter in the previous year.
Based on the above factors, Replimune Group, Inc gets an overall score of 2/5.